Stryker Corporation (NYSE:SYK) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET
Company Participants
Kevin Lobo - Chair and Chief Executive Officer
Jason Beach - Vice President, Finance and Investor Relations
Glenn Boehnlein - Vice President, Chief Financial Officer
Conference Call Participants
Lawrence Biegelsen - Wells Fargo Securities
Robert Marcus - JP Morgan
Ryan Zimmerman - BTIG
Joanne Wuensch - Citibank
Travis Steed - Bank of America
Matthew O’Brien - Piper Sandler
Shagun Singh Chadha - RBC
Matthew Miksic - Barclays
Steve Lichtman - Oppenheimer
Vijay Kumar - Evercore ISI
Matthew Taylor - Jefferies
Joshua Jennings - TD Cowen
Danielle Antalffy - UBS
Michael Matson - Needham
Caitlin Cronin - Canaccord
Jayson Bedford - Raymond James
Andrew Ranieri - Morgan Stanley
David Roman - Goldman Sachs
Operator
Welcome to the Second Quarter 2024 Stryker Earnings Call. My name is Luke, and I'm your operator for today's call. At this time, all participants are in a listen-only mode. Following the conference, we will conduct a question-and-answer session. This conference is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC.
I will now turn the call over to Mr. Kevin Lobo, Chair and Chief Executive Officer. You may proceed, sir.
Kevin Lobo
Welcome to Stryker's second quarter earnings call. Joining me today are Glenn Boehnlein, Stryker's CFO; and Jason Beach, Vice President of Finance and Investor Relations. For today's call, I will provide opening comments followed by Jason with the trends we saw during the quarter and some product updates. Glenn will then provide additional details regarding our quarterly results before we open the call to Q&A.
In the second quarter, we delivered strong organic growth sales of 9% against last year's nearly 12% comparable. Our performance included high single digit growth across both MedSurg and Neurotechnology and Orthopaedics and Spine. This broad performance reflects our diverse business model, sustained demand for our products and our team's strong commercial execution.
Our organic growth was well balanced between the US and international with both growing roughly 9%. Our strong results were led by double-digit organic growth in instruments, neuro cranial and Mako and high single digit growth in our medical, endoscopy, neurovascular, trauma and extremities and knee businesses.